MARKET

KYTX

KYTX

Kyverna Therapeutics
NASDAQ
7.80
-0.23
-2.86%
After Hours: 8.38 +0.58 +7.44% 19:48 03/27 EDT
OPEN
8.03
PREV CLOSE
8.03
HIGH
8.43
LOW
7.71
VOLUME
688.36K
TURNOVER
--
52 WEEK HIGH
13.67
52 WEEK LOW
1.780
MARKET CAP
471.43M
P/E (TTM)
-2.1402
1D
5D
1M
3M
1Y
5Y
1D
Kyverna Therapeutics files $300M mixed securities shelf
Seeking Alpha · 2d ago
Analysts Offer Insights on Healthcare Companies: Hyperion DeFi (HYPD), Kyverna Therapeutics, Inc. (KYTX) and Medios AG (OtherMEDOF)
TipRanks · 3d ago
Kyverna Therapeutics GAAP EPS of -$0.80 beats by $0.05
Seeking Alpha · 3d ago
KYVERNA THERAPEUTICS INC - MAY OFFER UP TO $300 MLN IN SECURITIES - SEC FILING
Reuters · 3d ago
Kyverna Therapeutics FY2025 net loss widens 27% to $(161) million; interest expense jumps 244% to $(489,000)
Reuters · 3d ago
Kyverna Therapeutics FY2025 net loss widens 26.51% to $161 million; R&D expenses increase 18.84% to $134 million
Reuters · 3d ago
Press Release: Kyverna Therapeutics Provides -2-
Dow Jones · 3d ago
*Kyverna Therapeutics 4Q Loss/Shr 80c >KYTX
Dow Jones · 3d ago
More
About KYTX
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Webull offers Kyverna Therapeutics Inc stock information, including NASDAQ: KYTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYTX stock methods without spending real money on the virtual paper trading platform.